Ganave Medical Completes Hundreds of Millions RMB Financing to Advance Minimally Invasive Oncology and Smart Healthcare Solutions

Recently, Curaway, a premium medical device company dedicated to precise therapeutic solutions in the minimally invasive field, announced the completion of its Series B financing round, amounting to hundreds of millions of yuan. The round was led by Hangshi Asset Management, with Haier Capital participating as a co-investor. The proceeds will be invested in the company’s continued development in areas such as precision minimally invasive surgery and smart healthcare, further strengthening Curaway’s competitive advantage in these sectors.

Zhejiang CuraWay Medical Technology Co., Ltd. Business CoverageMinimally Invasive Oncology, Peripheral Intervention, Precision Surgery, and Intelligent HealthcareFour Major Fields: With a deeply experienced R&D team, we are committed to building an innovative Chinese enterprise in high-end medical devices with global reach.

Curaway adheres to the principles of “minimally invasive” and “intelligent” in the field of precision medicine, and has established a comprehensive portfolio of minimally invasive ablation products designed for diverse clinical scenarios. Among these,Percutaneous Biopsy Needle Series, Tumor Radiofrequency Ablation Needle SeriesThe products have been fully launched and are on sale; multiple blockbusterEnergy Ablation DeviceandSmart Medical ProductsEnterRegistration and Clinical Phases, with product performance on par with top-tier international products and holding multiple core invention patents.

ExceptMinimally Invasive OncologyBeyond this core strategic thread, the company has proactively positioned itself inSmart Healthcarefield, independently developedPuncture Navigation and Positioning System, empowering precision therapy for the company’s biopsy and ablation product portfolios in the field of oncological intervention. As intelligent healthcare emerges as a key industry direction and experiences robust growth, Curaway, a pioneer in the development of intelligent medical solutions, will continue to deepen its focus in this sector. Leveraging its substantial and solid technical reserves accumulated over many years, the company will persistently iterate and expand its offerings, further enhancing its brand influence and promoting the advancement of medical technology.

Upholding the philosophy of “Precision in Action, CuraWay for Life,” the company delivers high-quality treatment solutions aligned with value-based medicine—characterized by minimal invasiveness, fewer complications, and faster recovery—to build a brand trusted by physicians and patients worldwide and achieve win-win outcomes for all stakeholders.

Project Lead, Hangzhou Industrial Asset ManagementIt stated that Curaway focuses on the entire diagnostic and therapeutic workflow for minimally invasive tumor treatment, possessing advanced technologies comparable to international brands in four key areas: tumor needle biopsy, intelligent interventional localization, minimally invasive therapy, and precision surgery. The company is committed to changing the current competitive landscape dominated by imported foreign brands. Hangshi Asset Management remains bullish on Curaway’s dedicated efforts in the field of minimally invasive tumor intervention, expecting the company to provide comprehensive, professional device support solutions for physicians in the future. Its cost-effective product offerings will also bring more treatment options to tumor patients, thereby benefiting society.

Project Lead, Haier CapitalIt stated that, as a platform-based medical company in minimally invasive surgery, Curaway possesses foundational R&D and manufacturing capabilities in energy platform technology, along with a comprehensive product portfolio and the ability to expand into overseas markets. Haier Capital is optimistic about the company’s sustained development in the field of minimally invasive surgery and its significant potential to become a leading Chinese-made medical device platform enterprise. It also looks forward to collaborating with Curaway on the Haier IoT Ecological Medical Platform to co-create solutions in the field of comprehensive tumor treatment.

Project Leader at Haibang Fenghua, an Existing ShareholderCuraway possesses a diverse portfolio of energy platform technologies in the field of minimally invasive surgical diagnosis and treatment, including radiofrequency ablation, irreversible electroporation (pulsed field ablation), and plasma technologies. The company has also independently established a comprehensive production and processing supply chain for medical consumables such as needle instruments. Leveraging its robust technical capabilities, extensive product lineup, and strong clinical resources, Curaway has emerged as a platform-type enterprise in the realm of intelligent minimally invasive diagnosis and treatment. In 2022, Curaway is set to receive regulatory approvals for multiple core products, further accelerating its commercialization efforts. Hangzhou Haibang Fenghua Investment Management Co., Ltd. remains optimistic about the company’s expansion capabilities in intelligent minimally invasive diagnosis and treatment and looks forward to seeing Curaway achieve greater success in its future product deployments and commercialization initiatives.